Cancer/Testis OIP5 and TAF7L Genes are Up-Regulated in Breast Cancer

  • Mobasheri, Maryam Beigom (Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences) ;
  • Shirkoohi, Reza (Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences) ;
  • Modarressi, Mohammad Hossein (Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences)
  • Published : 2015.06.26


Breast cancer still remains as the most frequent cancer with second mortality rate in women worldwide. There are no validated biomarkers for detection of the disease in early stages with effective power in diagnosis and therapeutic approaches. Cancer/testis antigens are recently promising tumor antigens and suitable candidates for targeted therapies and generating cancer vaccines. We conducted the present study to analyze transcript changes of two cancer/testis antigens, OIP5 and TAF7L, in breast tumors and cell lines in comparison with normal breast tissues by quantitative real time RT-PCR for the first time. Significant over-expression of OIP5 was observed in breast tumors and three out of six cell lines including MDA-MB-468, T47D and SKBR3. Not significant expression of TAF7L was evident in breast tumors but significant increase was noted in three out of six cell lines including MDA-MB-231, BT474 and T47D. OIP5 has ssignificant role in chromatin organization and cell cycle control during cell cycle exit and normal chromosome segregation during mitosis and TAF7L is a component of the transcription factor IID, which is involved in transcription initiation of most protein coding genes. TAF7Lis located at X chromosome and belongs to the CT-X gene family of cancer/testis antigens which contains about 50% of CT antigens, including those which have been used in cancer immunotherapy.


Breast cancer biomarkers;targeted therapy;cancer/testis genes;OIP5;TAF7L


Supported by : Tehran University of Medical Sciences


  1. Akinloye O, Gromoll J, Callies C, Nieschlag E, Simoni M (2007). Mutation analysis of the X-chromosome linked, testis-specific TAF7L gene in spermatogenic failure. Andrologia, 39, 190-5.
  2. Azam R, Ghafouri-Fard S, Tabrizi M, Modarressi MH, Ebrahimzadeh-Vesal R, et al (2014). Lactobacillus acidophilus and Lactobacillus crispatus culture supernatants downregulate expression of cancer-testis genes in the MDAMB-231 cell line. Asian Pac J Cancer Prev, 15, 4255-9.
  3. Caballero OL, Chen YT (2009). Cancer/testis [CT] antigens: potential targets for immunotherapy. Cancer Sci, 100, 2014-21.
  4. Charafe-Jauffret, Ginestier C, Monville F, et al (2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene, 25, 2273-84.
  5. Chun H-K, Chung K-S, Kim HC, et al (2010). OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers. BMB Rep, 43, 349-54.
  6. Cheng Y, Buffone MG, Kouadio M, et al (2007). Abnormal sperm in mice lacking the Taf7l gene. Mol Cell Biol, 27, 2582-9.
  7. Connallon T, Clark AG (2010). Sex linkage, sex-specific selection, and the role of recombination in the evolution of sexually dimorphic gene expression. Evolution, 64, 3417-42.
  8. Deborah L Holliday, Valerie Speirs (2011). Choosing the right cell line for breast cancer research. Holliday Speirs Breast Cancer Res, 13, 215.
  9. Dianatpour M, Mehdipour P, Nayernia K, et al (2012). Expression of testis specific genes TSGA10, TEX101 and ODF3 in breast cancer. Iran Red Cescent Med J, 14, 722-6.
  10. Eisenberg ML, Betts P, Herder D, Lamb DJ, Lipshultz L (2013). Increased risk of cancer among azoospermic men. FertilSteril, 100, 681-5.
  11. Fujita Y, Hayashi T, Kiyomitsu T, et al (2007). Priming of centromere for CENP-A recruitment by human hMis18alpha, hMis18beta, and M18BP1. Dev Cell, 12, 17-30.
  12. Freitas M, Malheiros S, Stavale JN, et al (2013). Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget, 4, 636-46.
  13. Gan B, Sahin E, Jiang S, et al (2008). mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci USA, 105, 19384-9.
  14. Ghafouri-Fard S, Modarressi MH (2009). Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med, 12, 395-404.
  15. Ghafouri-Fard S, Shamsi R, Seifi-Alan M, Javaheri M, Tabarestani S (2014). Cancer-testis genes as candidates for immunotherapy in breast cancer. Immunother, 6, 165-79.
  16. Gong M, Xu Y, Dong W, et al (2013). Expression of Opa interacting protein 5 (OIP5) is associated with tumor stage and prognosis of clear cell renal cell carcinoma. Acta Histochem, 115, 810-5.
  17. Harris L, Fritsche H, Mennel R, et al (2007). Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 25, 5287-312.
  18. Inoue K, Maeda N, Mori T, et al (2014). Possible involvement of Opa-interacting protein 5 in adipose proliferation and obesity. PLoS One, 6, 9.
  19. Kelly RJ, Giaccone G (2011). Lung cancer vaccines. Cancer J, 17, 302-8.
  20. Kimmins S, Kotaja N, Davidson I, Sassone-Corsi P (2004). Testis-specific transcription mechanisms promoting male germ-cell differentiation. Reproduction, 128, 5-12.
  21. Miryounesi M, Nayernia K, Mobasheri MB, et al (2014). Evaluation of in vitro spermatogenesis system effectiveness to study genes behavior: monitoring the expression of the testis specific 10 (Tsga10) gene as a model. Arch Iran Med, 17, 692-7.
  22. Mobasheri MB, Jahanzad I, Mohagheghi MA, et al (2007). Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. Cancer Detect Prev, 31, 296-302.
  23. Nakamura Y, Tanaka F, Nagahara H, et al (2007). Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer. Ann Surg Oncol, 14, 885-92.
  24. Oh HR, An CH, Yoo NJ, Lee SH (2014). Frameshift mutations of TAF7L Gene, a core component for transcription by RNA polymerase II, in colorectal cancers. Pathol Oncol Res, 7, [Epub ahead of print].
  25. Reinius B, Shi C, Hengshuo L, et al (2010), Female-biased expression of long non-coding RNAs in domains that escape X-inactivation in mouse. BMC Genomics, 11, 614.
  26. Saini S, Jagadish N, Gupta A, Bhatnagar A, Suri A (2013 ). A novel cancer testis antigen, A-Kinase anchor protein 4 (AKAP4) is a potential biomarker for breast cancer. PLoS One, 8, 57095.
  27. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. Ca Cancer J Clin, 62, 10-29.
  28. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005). Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 5, 615-25.
  29. Slebos RJ, Yi Y, Ely K, et al (2006). Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res, 1, 12, 701-9.
  30. Whitehurst AW (2014). Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol, 54, 251-72.
  31. Zhou H, Grubisic, Zheng K, et al (2013).Taf7l cooperates with Trf2 to regulate spermiogenesis. Proc Natl Acad Sci USA, 15, 16886-91.
  32. Zhou H, Wan B, Grubisic I, Kaplan T, Tjian R (2014). TAF7L modulates brown adipose tissue formation. Elife, 29, 10.7554.

Cited by

  1. Opa-interacting protein 5 modulates docetaxel-induced cell death via regulation of mitophagy in gastric cancer vol.39, pp.10, 2017,
  2. OIP5 Expression Sensitize Glioblastoma Cells to Lomustine Treatment vol.66, pp.3, 2018,
  3. LncRNA OIP5-AS1 is overexpressed in undifferentiated oral tumors and integrated analysis identifies as a downstream effector of stemness-associated transcription factors vol.8, pp.1, 2018,